Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Type & Diseases The global artificial cornea and corneal implant market will witness a robust CAGR of 6.9%, valued at $ 421 million in 2021, expected to appreciate and reach $ 767.50 million by 2030, confirms Strategic Market Research. The artificial cornea transplantation method involves suturing natural cornea tissue from a donor’s eye to replace a specific layer of the cornea. However, there is a global shortage of cornea donors and eye and tissue banking since these are not prevalent in various countries. Meanwhile, there is always a risk that the human eye will reject the transplantation process, resulting in infection or visual loss. Cornea implants treat keratoconus, degenerative conditions, and many more. Keratoconus is a condition of the eye cornea’s structure, causing vision loss and affects about one in every 2,000 people, usually starting in puberty and progressing into the mid-30s. In addition, an artificial cornea may be supplied to individuals with repeated corneal graft failure. A keratoprosthesis (KPro) is an artificial cornea material implant made of synthetic or prosthetic material. The Boston keratoprosthesis (Boston KPro) is the most prevalent one. In other terms, it is a surgical process involving replacing a defective cornea with an artificial cornea. Usually, keratoprosthesis is indicated after one or more donor corneal transplants have failed. Polymers like silica are used to create artificial cornea tissue. Artificial cornea implants are of two types, i.e., Synthetic cornea implants and biosynthetic cornea implants. The Effects of Covid-19 on Artificial Corneas and Corneal Implant Market Due to lockdowns and limits enacted to prevent the spread of the COVID-19 epidemic, the number of patient visits to clinics decreased significantly in the first and second quarters of 2020. As a result, Hospitals and clinics perform fewer elective eye procedures each week than they did in the past. According to an article in Ophthalmology Times, elective procedures have decreased from 200 to only ten each week. In addition, in countries such as the United States, patient visits to examination facilities have been reduced by 15%. According to the same article, it was reported that ophthalmology suffered a considerable loss of patient volume during the coronavirus disease (COVID-19) pandemic. During the starting phases of the COVID-19 outbreak, the worldwide government-imposed restrictions and prohibitions on medical operations and elective surgeries to restrict the virus’s contamination. Due to these restrictions, artificial cornea makers struggled to give in-person product presentations, operate at total capacity, and attend or organize conferences. Furthermore, due to lockdown in APAC nations such as China and India, the shipment & production of ophthalmics were delayed; these restrictions hindered the demand for ophthalmic surgeries. Market Dynamics Globally, the number of people suffering from severe eye disorders rises, and vision loss is becoming a significant public health concern. The prevalence of eye diseases such as diabetic retinopathy and ocular hypertension has increased due to the rising number of chronic diseases such as diabetes and hypertension (glaucoma) coupled with aging. In addition, the number of people who are blind or have limited eyesight is also predicted to rise significantly. Market Drivers: Increasing Incidences of Corneal Blindness, Eye Injury, and Scare Number of Cornea Donors Driving the Growth of the Market Corneal blindness affects around 10 million individuals on a worldwide basis. As a result, the critical factor driving the expansion of artificial cornea implants is the increased incidence of corneal blindness. Furthermore, the scarcity of human cornea donors has contributed to the market’s rapid development. Moreover, when the number of trauma cases rises, there is a greater risk of eye injury, which will drive the market forward. The chance of nerve regeneration following a human donor cornea transplant is low, whereas a biosynthetic cornea implant has a high probability of nerve regeneration after implantation. In heavily populated regions like India, donors for corneas are scarce, and patients with corneal blindness must wait for a long time for corneal transplants. Around 6.8 million people in the country have poor vision in one eye due to corneal abnormalities, while approximately one million people have poor vision in both eyes. Restraint: Rejection of Alloplastic Artificial Corneas and the Costly Implant Surgery Set to Limit the Market Growth The human eye’s rejection of alloplastic artificial corneas will be a significant problem limiting the global market for artificial cornea implants. Furthermore, because artificial cornea implant surgery is costly, its adoption is minimal in emerging nations, which will stifle market growth throughout the forecasted period. Furthermore, the scarcity of human cornea donors and the high risk of grafting artificial cornea implants have significantly impacted the global market. Patients and the end-users will have to pay a premium for OCT diagnostic services and OCT angiography. According To Ophthalmology Magazine, the OCT tests are used in 3–12% of the total visits in a typical general ophthalmology practice. In addition, the expenditures for equipment upkeep, staffing, and training are all substantial. These factors influence the clinic’s and small diagnostic center’s purchase decisions for such expensive equipment, and hence the market growth is expected to be limited. Opportunity: The Increasing Demand for Artificial Cornea and Its Implant and Technological Enhancement in The Same Set Provide Various Opportunities in The Market The high prevalence of corneal blindness, along with a scarcity of corneal donors, is predicted to provide high-growth possibilities for corneal implant producers. Furthermore, because of the rising frequency of corneal infection, the artificial cornea implant market is expected to rise exponentially throughout the forecast period. In addition, the demand for these cornea implants has grown in the global market due to increased visual handicaps among working people due to clouded corneas. Market Analysis Of Different Segments Covered in the Report By Implantation Type Endothelial Keratoplasty Penetrating Keratoplasty Others By Disease Manifestation Keratoconus Fungal Keratitis Fuchs’ Dystrophy Others By Type Artificial Cornea Human Cornea By End-User Specialty Clinics & ASCs Hospitals Regional Coverage Analysis North America United States Canada Mexico Europe Germany France Italy Switzerland United Kingdom Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific LAMEA Brazil Israel South Africa Saudi Arabia Rest of LAMEA Type Analysis & Insights The ‘human cornea’ sector accounts for the largest Artificial Cornea and Corneal Implant market share by type. This market segment is predicted to spread awareness about corneal implantation and eye tissue donation, particularly in emerging countries. The ‘penetrating keratoplasty’ sector dominates the market based on the Implantation Type. Penetrating Keratoplasty dominates due to an increase in the number of patients with eye illnesses such as infectious keratitis and eyeball injury. Disease Manifestation Analysis & Insights By Disease manifestation, which is one of the segments, the ‘Fuchs’ dystrophy’ segment has the largest market share. Due to the increased prevalence of Eye related diseases and increased awareness among people about the early detection of the condition, this segment is predicted to develop rapidly. End-User Analysis & Insights The market is dominated by the ‘specialty clinics’ category based on the End-User. The decline in inpatient surgeries and the increasing preference for more minor invasive procedures contribute to this segment’s development. Patient preferences fuel the segment’s rise for effective treatment and worries about hospital-acquired illnesses. Most ambulatory surgical institutions prefer biosynthetic cornea implants rather than synthetic cornea implants. As a result, the worldwide artificial corneal implant market is likely to dominate biosynthetic corneal implants. Regional Analysis & Insights ‘North America’ has the largest share of the market by region. North America’s significant proportion is due to the region’s developed healthcare infrastructure, increased acceptance of sophisticated medical technologies, and a diverse presence of corneal implant manufacturers. Furthermore, because of the large population base, rising disposable income, and increased patient awareness of eye care, Asia-Pacific is predicted to grow fastest over the forecasted period. Artificial Cornea and Corneal Implant Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 421 Million The revenue forecast in 2030 USD 767.50 Million Growth rate CAGR of approximately 6.9% The base year for estimation 2021 Historical data 2017 – 2021 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Implantation Type, By Disease manifestation, By Type, By Application, By Region. By Implantation Type Endothelial Keratoplasty, Penetrating Keratoplasty, Others. By Disease Manifestation Keratoconus, Fungal Keratitis, Fuchs’ Dystrophy, Others. By Type Artificial Cornea, Human Cornea. By End-User Specialty Clinics & ASCs, Hospitals. By Region North America, Europe, Asia-Pacific, LAMEA. Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E., etc. Company Usability Profiles CorneaGen, AJL Ophthalmic, LinkoCare Life Sciences AB, Addition Technology, Mediphacos, Florida Lions Eye Bank, Presbia plc, Aurolab, EyeYon Medical, Advancing Sight Network, Massachusetts Eye and Ear, DIOPTEX GmbH, San Diego Eye Bank, SightLife, Cornea Biosciences. Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Global Artificial Cornea and Corneal Implant Market Competitive Landscape Analysis Key market players operating in the market include CorneaGen, AJL Ophthalmic, LinkoCare Life Sciences AB, Addition Technology, Mediphacos, Florida Lions Eye Bank, Presbia plc, Aurolab, EyeYon Medical, Advancing Sight Network, Massachusetts Eye and Ear DIOPTEX GmbH, San Diego Eye Bank, SightLife, Cornea Biosciences, Frequently Asked Question About This Report Which artificial cornea and corneal implant market, by type, have been included in this report? By type Penetrating Keratoplasty and Endothelial Keratoplasty have been included in this report. Which geographical region is dominating in the artificial cornea and corneal implant market? North America is dominating in the market. Which are the leading transplant type in the global market? Penetrating Keratoplasty is the leading transplant type in the market. Which is the leading disease indication segment of the global market? Fuchs Dystrophy is the leading disease indication segment of the market. Which is the leading end-user segment of the global market? Specialty clinics are the leading end-user segment of the market. What will be the global market size in 2030? It is predicted to reach USD 767.50 Million by 2030. How big will the Artificial Cornea and Corneal Implant Market be? The global artificial cornea and corneal implant market size was $421 million in 2021. It is estimated to reach $767.50 million by 2030, representing a CAGR of 6.9% throughout the forecasted period of 2021-2030. Sources https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438571/ Chapter 1. Introduction 1.1 Study Objectives 1.2 Market Definition Table 1 Inclusions and Exclusions 1.3 Study Scope 1.3.1 Markets Covered Figure 01: Market Segmentation 1.3.2 Geographic Scope Figure 02: Market Geography covered 1.3.3 Years Considered 1.4 Stakeholders Chapter 2. Research Methodology 2.1 Data Procurement 2.2 Paid Database 2.2.1 Secondary Data 2.1.2.1 Key Secondary sources 2.2.2 Primary Data 2.2.2.1 Primary sources 2.2.2.2 Key industry insights 2.2.2.3 Primary interviews with experts 2.2.2.4 Key primary respondent list 2.3 Market Size Estimation 2.4 Bottom-Up and Top-Down Approaches 2.4.1 Bottom-Up Approach 2.4.1.1 Approach for arriving at market size by bottom-up analysis Figure 03: Market: Bottom-Up Approach 2.4.2 Top-Down Approach 2.4.2.1 Approach for Capturing Market Size by Top-Down Analysis Figure 04: Market: Top-Down Approach 2.5 Market Breakdown and Data Triangulation Figure 05: Data Triangulation 2.6 Research Methodology 2.7 Risk Assessment Table 2: Risk Assessment Chapter 3. Executive Summary 3.1 Market: Post-Covid-19 Figure 06: Impact of Covid-19 on Market 3.1.1 Actual Scenario Figure 07: Realistic Scenario: Market, 2021–2030 (USD Million) 3.1.2 Pessimistic Scenario Figure 08: Pessimistic Scenario: Market, 2021–2030 (USD Million) 3.1.3 Optimistic Scenario Figure 09: Optimistic Scenario: Market, 2021–2030(USD Million) 3.1.4 Market Summary Figure 10: Human Cornea to Witness Highest CAGR in Market, By Type, During Forecast Period Figure 11: Specialty clinics to Witness Higher CAGR in Market for End-User Segment during Forecast Period Figure 12: Fuchs’ dystrophy for Disease manifestation to Register Highest CAGR in Market during Forecast Period Figure 13: Penetrating Keratoplasty for Implantation Type to Register Highest CAGR in Market during Forecast Period Figure 14: North America to Account for Largest Share of Global Market In 2021 Chapter 4. Market Definitions 4.1 Market Segmentation Figure 15: Market Segmentation Chapter 5. Industry Outlook 5.1 Artificial Cornea and Corneal Implant Market Snapshot 5.2 Global Market 5.2.1 Global Market, 2021 – 2030 (USD Million) 5.3 Regional Segment Analysis 5.3.1 Global Market, by region, 2021 - 2030 (USD Million) 5.4 Type Segment Analysis 5.4.1 Global Market, by Type, 2021 - 2030 (USD Million) 5.5 End-User Analysis 5.5.1 Global Market, By End-User, 2021 - 2030 (USD Million) 5.6 Disease manifestation Segment Analysis 5.6.1 Global Market, by Disease manifestation, 2021 - 2030 (USD Million) 5.7 By Disease manifestation Business Analysis 5.8 Value Chain Analysis 5.9 Market Variable Analysis 5.9.1 Market Drivers Analysis 5.9.2 Market Restraints Analysis 5.10 Business Environment Analysis Tool 5.10.1 Market PEST analysis 5.10.2 Market Porter’s analysis 5.11 Penetration & Growth Prospect Mapping Chapter 6. Market Overview 6.1 Introduction 6.2 Market Dynamics Figure 16 Market: Drivers, Restraints, Opportunities, and Challenges 6.2.1 Drivers Figure 17 Market Drivers and Their Impact 6.2.2 Restraints Figure 18 Market Restraints and Their Impact 6.2.3 Opportunities Figure 19 Market Opportunities and Their Impact 6.2.4 Challenges Figure 20 Market Challenges and Their Impact 6.3 Impact of Covid-19 on Market 6.4 Value Chain Analysis Figure 21 Value Chain Analysis: Market 6.5 Ecosystem Figure 22 Market: Ecosystem Table 3 Market: Ecosystem Figure 23 Revenue Shift in Market 6.6 Patent Analysis Table 4 Number of Patents Registered in Market in USA in Last 9 Years Figure 24 Top 15 Companies with Highest No. of Patents in Last 9 Years Figure 25 No of Patents Granted Per Year, 2019–2021 Table 5 List of Global Patents in Market 6.7 Trade Analysis Figure 26 Import Data for Artificial Cornea, By Country, 2016–2021 (USD Thousand) Table 6 Import Data for Human Cornea, By Country, 2016–2021 (USD Thousand) Figure 27 Export Data for Artificial Cornea, By Country, 2016–2021 (USD Thousand) Table 7 Export Data for Human Cornea, By Country, 2016–2021 (USD Thousand) 6.8 Tariff Analysis 6.9 Case Study Analysis 6.10 Porter’s Five Forces Analysis Table 8 Market: Porter’s Five Forces Analysis, 2021 6.10.1 Threat of New Entrants 6.10.2 Threat of Substitutes 6.10.3 Bargaining Power of Buyers 6.10.4 Bargaining Power of Suppliers 6.10.5 Degree of Competition 6.11 Technology Analysis 6.11.1 Trends in Technology (2014-2021) 6.11.2 Trends in Technology (2021-2030) Table 9 Key Regulations: Market 6.12 Pricing Analysis 6.12.1 Average Price Trend Analysis (By region, By Countries) Chapter 7. Competitive & Vendor Landscape 7.1 Company Market Share Analysis Table 10: Key Players market share Figure 28: Key players market share of companies 7.2 Manufacturers Artificial Cornea and Corneal Implant Manufacturing Sites, Area Served, Product Type 7.3 Market Competitive Situation and Trends 7.4 Manufacturers Mergers & Acquisitions, Expansion Plans Chapter 8. Global Market: Type Segment Analysis 8.1 Introduction 8.2 Sales Volume & Revenue Analysis (2021-2030) Table 11 Market, By Type, 2021–2030 (USD Million) Figure 29 Market, By Type Figure 30 Human Cornea Segment to Register Highest CAGR in Market During Forecast Period 8.3 Human Cornea 8.3.1 Human Cornea market, 2021 - 2030 (USD Million) Figure 31: Human Cornea market, 2021 - 2030 (USD Million) 8.4 Artificial Cornea 8.4.1 Artificial Cornea market, 2021 - 2030 (USD Million) Figure 32: Artificial Cornea market, 2021 - 2030 (USD Million) Chapter 9. Global Market: End-User Segment Analysis 9.1 Introduction 9.2 Sales Volume & Revenue Analysis (2021-2030) Table 12: Market, By End-User, 2021–2030 (USD Million) Figure 33: Market, By End-User, 2021–2030 (USD Million) Figure 34: Specialty Clinics Segment to Register Highest CAGR in Market during Forecast Period 9.3 Specialty Clinics & ASCs 9.3.1 Specialty Clinics & ASCs market, 2021 - 2030 (USD Million) Figure 35: Specialty Clinics & ASCs market, 2021 - 2030 (USD Million) 9.4 Hospitals 9.4.1 Hospitals market, 2021 - 2030 (USD Million) Figure 36: Hospitals market, 2021 - 2030 (USD Million) Chapter 10. Global Market: Disease manifestation Segment Analysis 10.1 Introduction 10.2 Sales Volume & Revenue Analysis (2021-2030) Table 13: Market, By Disease manifestation, 2021–2030 (USD Million) Figure 37: Market, By Disease manifestation, 2021–2030 (USD Million) Figure 38: Fuchs’ dystrophy Segment to Register Highest CAGR in Market during Forecast Period 10.3 Keratoconus 10.3.1 Keratoconus market, 2021 - 2030 (USD Million) Figure 39: Keratoconus market, 2021 - 2030 (USD Million) 10.4 Fungal Keratitis 10.4.1 Fungal Keratitis market, 2021 - 2030 (USD Million) Figure 40: Fungal Keratitis market, 2021 - 2030 (USD Million) 10.5 Fuchs’ Dystrophy 10.5.1 Fuchs’ Dystrophy market, 2021 - 2030 (USD Million) Figure 41: Fuchs’ Dystrophy market, 2021 - 2030 (USD Million) 10.6 Others 10.6.1 Other Disease manifestation market, 2021 - 2030 (USD Million) Figure 42: Other Disease manifestation market, 2021 - 2030 (USD Million) Chapter 11. Global Market: Implantation Type Segment Analysis 11.1 Introduction 11.2 Sales Volume & Revenue Analysis (2021-2030) Table 14: Market, By Implantation Type, 2021–2030 (USD Million) Figure 43: Market, By Implantation Type, 2021–2030 (USD Million) Figure 44: Penetrating Keratoplasty Segment to Register Highest CAGR in Market during Forecast Period 11.3 Endothelial Keratoplasty 11.3.1 Endothelial Keratoplasty market, 2021 - 2030 (USD Million) Figure 45: Endothelial Keratoplasty market, 2021 - 2030 (USD Million) 11.4 Penetrating Keratoplasty 11.4.1 Penetrating Keratoplasty market, 2021 - 2030 (USD Million) Figure 46: Penetrating Keratoplasty market, 2021 - 2030 (USD Million) 11.5 Others 11.5.1 Other Implantation Type market, 2021 - 2030 (USD Million) Figure 47: Other Implantation Type market, 2021 - 2030 (USD Million) Chapter 12. Global Market: Regional Outlook 12.1 North America Figure 48: North America Market, By Revenue Forecast (2021-2030) 12.1.1 North America Market, by country, 2021 - 2030 (USD Million) Table 15: North America Market, by Country, 2021-2030 Figure 49: North America Market 12.1.2 North America Market, by Type, 2021 - 2030 (USD Million) Table16: North America Market, by Type, 2021 - 2030 (USD Million) Figure 50: North America Market, by Type, 2021 - 2030 (USD Million) 12.1.3 North America Market, by End-User, 2021 - 2030 (USD Million) Table 17: North America Market, by End-User, 2021 - 2030 (USD Million) Figure 51: North America Market, by End-User, 2021 - 2030 (USD Million) 12.1.4 North America Market, by Disease manifestation, 2021 - 2030 (USD Million) Table 18: North America Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 52: North America Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.1.5 U.S. 12.1.5.1 U.S. Market, by Type, 2021 - 2030 (USD Million) Figure 53: U.S. Market, by Type, 2021 - 2030 (USD Million) 12.1.5.2 U.S. Market, by End-User, 2021 - 2030 (USD Million) Figure 54: U.S. Market, by End-User, 2021 - 2030 (USD Million) 12.1.5.3 U.S. Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 55: U.S. Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.1.6 Canada 12.1.6.1 Canada Market, by Type, 2021 - 2030 (USD Million) Figure 56: Canada Market, by Type, 2021 - 2030 (USD Million) 12.1.6.2 Canada Market, by End-User, 2021 - 2030 (USD Million) Figure 57: Canada Market, by End-User, 2021 - 2030 (USD Million) 12.1.6.3 Canada Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 58: Canada Market, by End-User, 2021 - 2030 (USD Million) 12.1.6.4 Canada Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 59: Canada Market, by End-User, 2021 - 2030 (USD Million) 12.2 Europe Figure 60: Europe Market, By Revenue Forecast (2021-2030) 12.2.1 Europe Market, by country, 2021 - 2030 (USD Million) Table 19: Europe Market, by country, 2021 - 2030 (USD Million) Figure 61: Europe Market, by country, 2021 - 2030 (USD Million) 12.2.2 Europe Market, by Type, 2021 - 2030 (USD Million) Table 20: Europe Market, by Type, 2021 - 2030 (USD Million) Figure 62: Europe Market, by Type, 2021 - 2030 (USD Million) 12.2.3 Europe Market, by End-User, 2021 - 2030 (USD Million) Table 21: Europe Market, by End-User, 2021 - 2030 (USD Million) Figure 63: Europe Market, by End-User, 2021 - 2030 (USD Million) 12.2.4 Europe Market, by Disease manifestation, 2021 - 2030 (USD Million) Table 22: Europe Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 64: Europe Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.2.5 U.K. 12.2.5.1 U.K. Market, by Type, 2021 - 2030 (USD Million) Figure 65: U.K. Market, by Type, 2021 - 2030 (USD Million) 12.2.5.2 U.K. Market, by End-User, 2021 - 2030 (USD Million) Figure 66: U.K. Market, by End-User, 2021 - 2030 (USD Million) 12.2.5.3 U.K. Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 67: U.K. Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.2.6 Germany 12.2.6.1 Germany Market, by Type, 2021 - 2030 (USD Million) Figure 68: Germany Market, by Type, 2021 - 2030 (USD Million) 12.2.6.2 Germany Market, by End-User, 2021 - 2030 (USD Million) Figure 69: Germany Market, by End-User, 2021 - 2030 (USD Million) 12.2.6.3 Germany Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 70: Germany Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.2.7 France 12.2.7.1 France Market, by Type, 2021 - 2030 (USD Million) Figure 71: France Market, by Type, 2021 - 2030 (USD Million) 12.2.7.2 France Market, by End-User, 2021 - 2030 (USD Million) Figure 72: France Market, by End-User, 2021 - 2030 (USD Million) 12.2.7.3 France Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 73: France Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.2.8 Rest of Europe 12.2.8.1 Rest of Europe Market, by Type, 2021 - 2030 (USD Million) Figure 74: Rest of Europe Market, by Type, 2021 - 2030 (USD Million) 12.2.8.2 Rest of Europe Market, by End-User, 2021 - 2030 (USD Million) Figure 75: Rest of Europe Market, by End-User, 2021 - 2030 (USD Million) 12.2.8.3 Rest of Europe Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 76: Rest of Europe Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.3 Asia Pacific Figure 77: Asia Pacific Market, By Revenue Forecast (2021-2030) 12.3.1 Asia Pacific Market, by country, 2021 - 2030 (USD Million) Table 23: Asia Pacific Market, by country, 2021 - 2030 (USD Million) Figure 78: Asia Pacific Market, by country, 2021 - 2030 (USD Million) 12.3.2 Asia Pacific Market, by Type, 2021 - 2030 (USD Million) Table 24: Asia Pacific Market, by Type, 2021 - 2030 (USD Million) Figure 79: Asia Pacific Market, by Type, 2021 - 2030 (USD Million) 12.3.3 Asia Pacific Market, by End-User, 2021 - 2030 (USD Million) Table 25: Asia Pacific Market, by End-User, 2021 - 2030 (USD Million) Figure 80: Asia Pacific Market, by End-User, 2021 - 2030 (USD Million) 12.3.4 Asia Pacific Market, by Disease manifestation, 2021 - 2030 (USD Million) Table 26: Asia Pacific Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 81: Asia Pacific Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.3.5 China 12.3.5.1 China Market, by Type, 2021 - 2030 (USD Million) Figure 82: China Market, by Type, 2021 - 2030 (USD Million) 12.3.5.2 China Market, by End-User, 2021 - 2030 (USD Million) Figure 83: China Market, by End-User, 2021 - 2030 (USD Million) 12.3.5.3 China Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 84: China Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.3.6 India 12.3.6.1 India Market, by Type, 2021 - 2030 (USD Million) Figure 85: India Market, by Type, 2021 - 2030 (USD Million) 12.3.6.2 India Market, by End-User, 2021 - 2030 (USD Million) Figure 86: India Market, by End-User, 2021 - 2030 (USD Million) 12.3.6.3 India Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 87: India Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.3.7 Japan 12.3.7.1 Japan Market, by Type, 2021 - 2030 (USD Million) Figure 88: Japan Market, by Type, 2021 - 2030 (USD Million) 12.3.7.2 Japan Market, by End-User, 2021 - 2030 (USD Million) Figure 89: Japan Market, by End-User, 2021 - 2030 (USD Million) 12.3.7.3 Japan Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 90: Japan Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.3.8 South Korea 12.3.8.1 South Korea Market, by Type, 2021 - 2030 (USD Million) Figure 91: South Korea Market, by Type, 2021 - 2030 (USD Million) 12.3.8.2 South Korea Market, by End-User, 2021 - 2030 (USD Million) Figure 92: South Korea Market, by End-User, 2021 - 2030 (USD Million) 12.3.8.3 South Korea Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 93: South Korea Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.3.9 Rest of APAC 12.3.9.1 Rest of APAC Market, by Type, 2021 - 2030 (USD Million) Figure 94: Rest of APAC Market, by Type, 2021 - 2030 (USD Million) 12.3.9.2 Rest of APAC Market, by End-User, 2021 - 2030 (USD Million) Figure 95: Rest of APAC Market, by End-User, 2021 - 2030 (USD Million) 12.3.9.3 Rest of APAC Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 96: Rest of APAC Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.4 Latin America Figure 97: Latin America Market, By Revenue Forecast (2021-2030) 12.4.1 Latin America Market, by country, 2021 - 2030 (USD Million) Table 27: Latin America Market, by country, 2021 - 2030 (USD Million) Figure 98: Latin America Market, by country, 2021 - 2030 (USD Million) 12.4.2 Latin America Market, by Type, 2021 - 2030 (USD Million) Table 28: Latin America Market, by Type, 2021 - 2030 (USD Million) Figure 99: Latin America Market, by Type, 2021 - 2030 (USD Million) 12.4.3 Latin America Market, by End-User, 2021 - 2030 (USD Million) Table 29: Latin America Market, by End-User, 2021 - 2030 (USD Million) Figure 100: Latin America Market, by End-User, 2021 - 2030 (USD Million) 12.4.4 Latin America Market, by Disease manifestation, 2021 - 2030 (USD Million) Table 30: Latin America Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 101: Latin America Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.4.5 Brazil 12.4.5.1 Brazil Market, by Type, 2021 - 2030 (USD Million) Figure 102: Brazil Market, by Type, 2021 - 2030 (USD Million) 12.4.5.2 Brazil Market, by End-User, 2021 - 2030 (USD Million) Figure 103: Brazil Market, by End-User, 2021 - 2030 (USD Million) 12.4.5.3 Brazil Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 104: Brazil Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.4.6 Mexico 12.4.6.1 Mexico Market, by Type, 2021 - 2030 (USD Million) Figure 105: Mexico Market, by Type, 2021 - 2030 (USD Million) 12.4.6 2 Mexico Market, by End-User, 2021 - 2030 (USD Million) Figure 106: Mexico Market, by End-User, 2021 - 2030 (USD Million) 12.4.6.3 Mexico Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 107: Mexico Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.4.7 Rest of the Latin America 12.4.7.1 Rest of the Latin America Market, by Type, 2021 - 2030 (USD Million) Figure 108: Rest of the Latin America Market, by Type, 2021 - 2030 (USD Million) 12.4.7.2 Rest of the Latin America Market, by End-User, 2021 - 2030 (USD Million) Figure 109: Rest of the Latin America Market, by End-User, 2021 - 2030 (USD Million) 12.4.7.3 Rest of the Latin America Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 110: Rest of the Latin America Market, by Disease manifestation, 2021 - 2030 (USD Million) 12.5 MEA Figure 111: MEA Market, By Revenue Forecast (2021-2030) 12.5.1 MEA Market, by Type, 2021 - 2030 (USD Million) Figure 112: MEA Market, by Type, 2021 - 2030 (USD Million) 12.5.2 MEA Market, by End-User, 2021 - 2030 (USD Million) Figure 113: MEA Market, by End-User, 2021 - 2030 (USD Million) 12.5.3 MEA Market, by Disease manifestation, 2021 - 2030 (USD Million) Figure 114: MEA Market, by Disease manifestation, 2021 - 2030 (USD Million) Chapter 13. Competitive Landscape 13.1 CorneaGen. 13.1.1 Company overview 13.1.2 Financial performance 13.1.3 Product Portfolio Analysis 13.1.4 Business Strategy & Recent Development 13.2 AJL Ophthalmic. 13.2 .1 Company overview 13.2 .2 Financial performance 13.2 .3 Product Portfolio Analysis 13.2 .4 Business Strategy & Recent Development 13.3 LinkoCare Life Sciences AB. 13.3.1 Company overview 13.3.2 Financial performance 13.3.3 Product Portfolio Analysis 13.3.4 Business Strategy & Recent Development 13.4 Addition Technology. 13.4.1 Company overview 13.4.2 Financial performance 13.4.3 Product Portfolio Analysis 13.4.4 Business Strategy & Recent Development 13.5 Mediphacos. 13.5.1 Company overview 13.5.2 Financial performance 13.5.3 Product Portfolio Analysis 13.5.4 Business Strategy & Recent Development 13.6 Florida Lions Eye Bank. 13.6.1 Company overview 13.6.2 Financial performance 13.6.3 Product Portfolio Analysis 13.6.4 Business Strategy & Recent Development 13.7 Presbia plc. 13.7.1 Company overview 13.7.2 Financial performance 13.7.3 Product Portfolio Analysis 13.7.4 Business Strategy & Recent Development 13.8 Aurolab. 13.8.1 Company overview 13.8.2 Financial performance 13.8.3 Product Portfolio Analysis 13.8.4 Business Strategy & Recent Development 13.9 EyeYon Medical. 13.9.1 Company overview 13.9.2 Financial performance 13.9.3 Product Portfolio Analysis 13.9.4 Business Strategy & Recent Development 13.10 Advancing Sight Network. 13.10.1 Company overview 13.10.2 Financial performance 13.10.3 Product Portfolio Analysis 13.10.4 Business Strategy & Recent Development 13.11 Massachusetts Eye and Ear. 13.11.1 Company overview 13.11.2 Financial performance 13.11.3 Product Portfolio Analysis 13.11.4 Business Strategy & Recent Development 13.12 DIOPTEX GmbH. 13.12.1 Company overview 13.12.2 Financial performance 13.12.3 Product Portfolio Analysis 13.12.4 Business Strategy & Recent Development 13.13 San Diego Eye Bank. 13.13.1 Company overview 13.13.2 Financial performance 13.13.3 Product Portfolio Analysis 13.13.4 Business Strategy & Recent Development 13.14 SightLife. 13.14.1 Company overview 13.14.2 Financial performance 13.14.3 Product Portfolio Analysis 13.14.4 Business Strategy & Recent Development 13.15 Cornea Biosciences. 13.15.1 Company overview 13.15.2 Financial performance 13.15.3 Product Portfolio Analysis 13.15.4 Business Strategy & Recent Development